# Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07457359/  
OnCo record `nct07457359` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in triple-negative breast cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.

## Summary

Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07457359 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 18 participants, started 2026-01-04 and due to reach its primary completion in 2028-01-04. Interventions recorded: SBRT; Toripalimab (anti-PD-1 antibody); Chemotherapy switch. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically confirmed triple-negative phenotype: ER \< 1 %, PR \< 1 % by IHC, HER2 negative (IHC 0/1+ or IHC 2+ with ISH negative)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: NEOTRIO-2
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07457359
- Phase: 2
- Setting: Neoadjuvant Toripalimab Combined With Preoperative Radiotherapy for Initial Chemotherapy-Nonresponding Triple-Negative Breast Cancer Patients (NEOTRIO-2)
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT07457359: https://clinicaltrials.gov/study/NCT07457359

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07457359.json